CYTO logo

Altamira Therapeutics (CYTO) EBIT

Annual EBIT

-$1.87 M
+$17.28 M+90.21%

December 1, 2023


Summary


Performance

CYTO EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCYTOprofitabilitymetrics:

Quarterly EBIT

N/A

June 1, 2024


Summary


Performance

CYTO Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherCYTOprofitabilitymetrics:

TTM EBIT

N/A

June 1, 2024


Summary


Performance

CYTO TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherCYTOprofitabilitymetrics:

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

CYTO EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+90.2%--
3 y3 years+79.8%--
5 y5 years+82.0%--

CYTO EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+90.2%
5 y5-yearat high+90.2%
alltimeall timeat high+93.8%

Altamira Therapeutics EBIT History

DateAnnualQuarterlyTTM
Dec 2023
-$1.87 M(-90.2%)
-
-
Dec 2022
-$19.15 M(+157.7%)
-
-
Dec 2021
-$7.43 M(-19.7%)
-
-
Dec 2020
-$9.26 M(+31.9%)
-
-
Dec 2019
-$7.02 M(-32.7%)
-
-
Dec 2018
-$10.43 M(-55.4%)
-$3.44 M(+17.9%)
-$10.42 M(-7.7%)
Sep 2018
-
-$2.92 M(+12.9%)
-$11.29 M(-20.0%)
Jun 2018
-
-$2.59 M(+75.5%)
-$14.12 M(-15.8%)
Mar 2018
-
-$1.47 M(-65.8%)
-$16.77 M(-28.0%)
Dec 2017
-$23.39 M(-20.5%)
-$4.31 M(-25.1%)
-$23.28 M(+2.5%)
Sep 2017
-
-$5.75 M(+9.7%)
-$22.71 M(-8.1%)
Jun 2017
-
-$5.24 M(-34.3%)
-$24.71 M(-12.0%)
Mar 2017
-
-$7.98 M(+113.9%)
-$28.07 M(-4.2%)
Dec 2016
-$29.41 M
-$3.73 M(-51.8%)
-$29.30 M(-4.5%)
Sep 2016
-
-$7.75 M(-9.9%)
-$30.69 M(+8.4%)
DateAnnualQuarterlyTTM
Jun 2016
-
-$8.60 M(-6.7%)
-$28.30 M(-10.2%)
Mar 2016
-
-$9.22 M(+80.2%)
-$31.52 M(+2.9%)
Dec 2015
-$30.04 M(+63.9%)
-$5.11 M(-4.6%)
-$30.62 M(+5.8%)
Sep 2015
-
-$5.36 M(-54.7%)
-$28.96 M(+6.7%)
Jun 2015
-
-$11.83 M(+42.2%)
-$27.13 M(+29.9%)
Mar 2015
-
-$8.32 M(+141.3%)
-$20.88 M(+8.9%)
Dec 2014
-$18.33 M(+11.1%)
-$3.45 M(-2.4%)
-$19.17 M(-2.7%)
Sep 2014
-
-$3.53 M(-36.7%)
-$19.70 M(-7.1%)
Jun 2014
-
-$5.58 M(-15.5%)
-$21.22 M(+2.1%)
Mar 2014
-
-$6.61 M(+65.9%)
-$20.77 M(+25.9%)
Dec 2013
-$16.50 M(+227.3%)
-$3.98 M(-21.1%)
-$16.50 M(+31.8%)
Sep 2013
-
-$5.05 M(-1.8%)
-$12.52 M(+67.5%)
Jun 2013
-
-$5.14 M(+120.0%)
-$7.47 M(+220.0%)
Mar 2013
-
-$2.34 M
-$2.34 M
Dec 2012
-$5.04 M
-
-

FAQ

  • What is Altamira Therapeutics annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Altamira Therapeutics?
  • What is Altamira Therapeutics annual EBIT year-on-year change?
  • What is the all time high quarterly EBIT for Altamira Therapeutics?
  • What is the all time high TTM EBIT for Altamira Therapeutics?

What is Altamira Therapeutics annual earnings before interest & taxes?

The current annual EBIT of CYTO is -$1.87 M

What is the all time high annual EBIT for Altamira Therapeutics?

Altamira Therapeutics all-time high annual earnings before interest & taxes is -$1.87 M

What is Altamira Therapeutics annual EBIT year-on-year change?

Over the past year, CYTO annual earnings before interest & taxes has changed by +$17.28 M (+90.21%)

What is the all time high quarterly EBIT for Altamira Therapeutics?

Altamira Therapeutics all-time high quarterly earnings before interest & taxes is -$1.47 M

What is the all time high TTM EBIT for Altamira Therapeutics?

Altamira Therapeutics all-time high TTM earnings before interest & taxes is -$2.34 M